Pathways to Access & Reimbursement Forum

In a session titled “Breaking Down the Latest Changes in US Drug Pricing and the Potential Impact on the Canadian Market,” Erin will provide an overview of the new Medicare drug pricing provisions in the United States, including identifying which drugs will be subject to negotiation, in the Inflation Reduction Act. Erin’s co-presenter will address the new law’s potential impacts on Canadian and other markets and analyze the implications for drug manufacturers.

The hybrid conference will provide health care practitioners with insights from key regulators and industry leaders on Canada’s access and reimbursement environment and how to build a successful market access and pricing plan for 2023.